A Study to Assess the Safety, Tolerability and Effectiveness of Nuedexta (Dextromethorphan 20 mg/Quinidine 10 mg) in the Treatment of Pseudobulbar Affect (PBA)

Trial Profile

A Study to Assess the Safety, Tolerability and Effectiveness of Nuedexta (Dextromethorphan 20 mg/Quinidine 10 mg) in the Treatment of Pseudobulbar Affect (PBA)

Completed
Phase of Trial: Phase IV

Latest Information Update: 28 Apr 2017

At a glance

  • Drugs Dextromethorphan/quinidine (Primary)
  • Indications Emotional lability
  • Focus Therapeutic Use
  • Acronyms PRISM-II
  • Sponsors Avanir Pharmaceuticals
  • Most Recent Events

    • 28 Apr 2017 Results of an exploratory analysis, presented at the 69th Annual Meeting of the American Academy of Neurology.
    • 08 Jun 2016 Full results from this trial published online in BMC Neurology, according to an Avanir Pharmaceuticals media release.
    • 08 Jun 2016 Results published in an Avanir Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top